phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer
phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Treatment of liver cancer remains challenging, due to a paucity of drugs that target critical dependencies. Sorafenib is a multikinase inhibitor that is approved as the standard therapy for advanced hepatocellular carcinoma patients, but it can only provide limited survival benefit for patients. To investigate the cause of this limited therapeutic...
Alternative Titles
Full title
phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2071127218
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2071127218
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/252452
How to access this item
https://www.proquest.com/docview/2071127218?pq-origsite=primo&accountid=13902
